[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-360465-105":59,"doc-detail-360465-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","cabozantinib-and-temozolomide-in-patients-with-advanced-progressive-neuroendocrine-tumors-a-phase-2-study","Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study","","Treatment options for advanced progressive neuroendocrine tumors (NETs) remain limited. Preclinical and early clinical evidence suggests cabozantinib plus temozolomide may show synergistic antitumor effects, including enhanced sensitivity through c-MET/ERK pathway modulation and possible antiangiogenic synergy. An open-label, single-arm phase 2 study assessed safety and efficacy of cabozantinib 40 mg daily with metronomic temozolomide 100 mg/m2/day (week on/off) in 37 patients. The primary ORR by blinded local review was 15%, while CBR reached 100% and median PFS was 28.5 months. Common grade ≥3 toxicities included lymphopenia, thrombocytopenia, diarrhea, and colitis, with no treatment-related deaths. MGMT deficiency and c-MET expression correlated with response, supporting larger controlled trials.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/cabozantinib-and-temozolomide-in-patients-with-advanced-progressive-neuroendocrine-tumors-a-phase-2-study/360465/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/cabozantinib-and-temozolomide-in-patients-with-advanced-progressive-neuroendocrine-tumors-a-phase-2-study/360465.png","ImageObject",300,407,{"name":92,"@type":93},"Dipper","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the primary endpoint of the phase 2 study?","Question",{"text":112,"@type":113},"The primary endpoint was overall response rate (ORR) assessed by blinded local review.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How did patients respond to cabozantinib plus temozolomide?",{"text":117,"@type":113},"ORR was 15%, which did not meet the primary endpoint, but clinical benefit rate (CBR) was 100% with a median progression-free survival (PFS) of 28.5 months.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key treatment-related adverse events and safety findings?",{"text":121,"@type":113},"The most frequent grade ≥3 treatment-related adverse events were lymphopenia, thrombocytopenia, diarrhea, and colitis. No treatment-related deaths were recorded.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},360465,1790410870,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1374404997633,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","| |  |  | |\n| --- | --- | --- | --- |\n| Article [https://doi.org/10.1038/s41467-026-71756-7](https://doi.org/10.1038/s41467-026-71756-7) |  |  |  |\n| Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study |  |  |  |\n| Received: 17 April 2025\u003Cbr>Accepted: 24 March 2026 Check for updates | A list of authors and their afﬁliations appears at the end of the paper\u003Cbr>Treatment options for patients with advanced neuroendocrine tumors (NETs) are limited. Preclinical and early clinical evidence suggest that cabozantiniband temozolomide may exert synergistic antitumor activity. We performed an open-label, single-arm, phase 2 study (NCT04893785) to assess the safety andefﬁcacy of cabozantinib and metronomic temozolomide in patients with advanced, progressive, well-differentiated NETs of gastroenteropancreatic, pulmonary or unknown origin. Patients received cabozantinib 40 mg daily and temozolomide 100 mg/m2/day one week on/one week off. The primary endpoint was overall response rate (ORR) by blinded local review. Secondary endpoints included progression-free survival (PFS), overall survival (OS), clinical beneﬁt rate (CBR), duration of response (DOR) and safety. Of the 37 patients enrolled, 14 harbored gastrointestinal NETs, 12 pancreatic NETs, 9 lung NETs and 2 NETs of unknown primary. Neoplasms were classiﬁed as G1, G2 or G3 in 9, 24 and 4 cases respectively. While all enrolled patients were assessable for toxicity, 33 met the criteria for per protocol assessment of efﬁcacy. The ORR was 15%(95% CI, 5-31%) and did not meet the primary endpoint. However, after a median follow-up of 19.2 months, the CBR was 100%(95% CI, 89.5-100%) and the median PFS was 28.5 months (95% CI, 16.8- 28.5 months). The median OS was not reached, with a 3-year OS rate of 68.5%( ± 9.1%). The median DOR was 19.5 months. Lymphopenia (16%), thrombocytopenia (11%), diarrhea (8%) and colitis (8%) emerged as the most frequent grade ≥3 treatment-related adverse events. No treatment-related deaths were recorded. Deﬁciency of O⁶-methylguanine–DNA methyltransferase (MGMT) and c-MET expression were associated with response. The proportion of the patients beneﬁtting of the treatment and its safety proﬁle justify larger, controlled studies to further investigate the added role of combining cabozantinib with metronomic temozolomide. ClinicalTrials.gov identiﬁer: NCT04893785. |  |  |\n| Neuroendocrine tumors (NETs) are heterogeneous malignancies originating from the diffuse neuroendocrine system1. According to the most updated analysis of the Surveillance, Epidemiology and End Results (SEER) program of the National Cancer Institute (NCI), the annual age- |  | adjusted incidence of NETs is 8.52 per 100,0002. Most commonly, NETs arise in the gastrointestinal tract, lungs, and pancreas, and substantial differences have been described in terms of biology, clinical behavior, and response to treatments according to the site of origin1. |  |\n\n e-mail: [s.tafuto@istitutotumori.na.it](s.tafuto@istitutotumori.na.it)  \nThe treatment landscape of advanced NETs has recently expanded. Treatment options for extrapancreatic NETs include somatostatin analogs (SSAs)3,4 and everolimus5. Sunitinib6 or alkylating agent chemotherapy, particularly with temozolomide-based regimens7, can also be considered for pancreatic NETs. Radioligand therapy with 177Lu-dotatate is approved for the treatment of patients with somatostatin receptor (SSTR)-positive gastroenteropancreatic (GEP)-NETs progressive on SSA8. Based on the results of the NETTER- 2 study9, 177Lu-dotatate has been recently approved by FDA but not EMA as frontline therapy in patients with advanced, welldifferentiated GEP-NETs with a Ki-67 proliferative index of 10–55%. Cabozantinib, an oral small-molecule inhibitor of multiple tyrosine kinases including VEGF receptors, MET, AXL, and RET has been recently investigated in the double-blind, randomized, placebocontrolled CABINET trial10. The tyrosi","cbCaisb6wrGgFj01","https://ap.wps.com/l/cbCaisb6wrGgFj01","pdf",3656230,14,"English","# Phase 2 study design\n## Endpoints and treatment regimen\n# Study population and outcomes\n## Response, survival, and duration of response\n# Safety and biomarker analyses\n## Adverse events and MGMT/c-MET associations","[{\"question\":\"What was the primary endpoint of the phase 2 study?\",\"answer\":\"The primary endpoint was overall response rate (ORR) assessed by blinded local review.\"},{\"question\":\"How did patients respond to cabozantinib plus temozolomide?\",\"answer\":\"ORR was 15%, which did not meet the primary endpoint, but clinical benefit rate (CBR) was 100% with a median progression-free survival (PFS) of 28.5 months.\"},{\"question\":\"What were the key treatment-related adverse events and safety findings?\",\"answer\":\"The most frequent grade ≥3 treatment-related adverse events were lymphopenia, thrombocytopenia, diarrhea, and colitis. No treatment-related deaths were recorded.\"}]","Cabozantinib and temozolomide in patients with advanced progressive neuroendocrine tumors: a phase 2 study | PDF",1790140195,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c01982460a5eb62ddfc00a0cb7805539.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/be0ea6dcd14de89967447fe175f0386f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2e28f9c89b944a1c3ea187327b077fd0.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/549dc893f1c307f52cf60f8439c27ae9.webp",980,1301]